Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is poised for strong growth and success due to its diverse product line, global presence, and commitment to innovation. The company's Medical Devices and Diagnostics segments face competition but remain differentiated due to their focus on technological advancements. Despite potential risks, Abbott's balanced growth trajectory, strong financials and a diversified business model make it a promising investment opportunity.

Bears say

Abbott Laboratories is facing major headwinds in its Medical Devices business due to unfavorable changes in healthcare regulation, pricing, and reimbursement, as well as product safety concerns and product liability. The company's diabetes segment also showed slower growth in Q1 due to a delayed renewal of an international tender and challenging year-over-year comparisons, which could impact future sales. While Abbott maintains a positive outlook for 2026, these factors combined with competition and a weaker-than-expected respiratory season could lead to disappointment for both investors and the company in the future. In the meantime, Abbott's diversified business model and potential for margin expansion could provide some stability.

Abbott Labs (ABT) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 18 analysts, Abbott Labs (ABT) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $129.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $129.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.